Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06432478




Registration number
NCT06432478
Ethics application status
Date submitted
11/01/2024
Date registered
29/05/2024
Date last updated
29/05/2024

Titles & IDs
Public title
3D Printed Custom Applicators for HDR BT (DISCO)
Scientific title
Study of 3D-printed Custom Applicators for Intracavitary HDR Gynaecological Brachytherapy (DISCO)
Secondary ID [1] 0 0
DISCO
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gynecologic Cancer 0 0
Endometrial Cancer 0 0
Vaginal Cancer 0 0
Vulva Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)
Cancer 0 0 0 0
Other cancer types
Reproductive Health and Childbirth 0 0 0 0
Other reproductive health and childbirth disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - 3D-printed custom applicator

Experimental: Gynaecological HDR brachytherapy patients - Using 3D-printed custom applicators to treat gynaecological HDR brachytherapy patients


Treatment: Devices: 3D-printed custom applicator
3D-printed custom applicator
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Successful treatment of gynaecological HDR brachytherapy patients with 3D printed intracavitary applicators.
Timepoint [1] 0 0
5 years
Secondary outcome [1] 0 0
To assess the patients radiation therapy acute and late toxicities using the CTCAE criteria
Timepoint [1] 0 0
5 years
Secondary outcome [2] 0 0
To compare quality of treatment plans generated for 3D-printed moulds and cylindrical applicators assessed by dosimetric indices, statistical analysis (p-value) and comparison with international guidelines.
Timepoint [2] 0 0
5 years
Secondary outcome [3] 0 0
Determine feasibility of a pre-planned MR-only procedure
Timepoint [3] 0 0
5 years
Secondary outcome [4] 0 0
To determine the feasibility of an initial CT-only process by comparing initial and final CT plan dosimetry assessed by dosimetric indices, clinical tolerances, and statistical analysis (p-value).
Timepoint [4] 0 0
5 years
Secondary outcome [5] 0 0
Determine feasibility of optimising 3D-printed applicator design based on the cylinder fitting procedure
Timepoint [5] 0 0
5 years
Secondary outcome [6] 0 0
To measure resources such as procedure times and demonstrate acceptable timescales for the process
Timepoint [6] 0 0
5 years
Secondary outcome [7] 0 0
To define the resource costs associated with the 3D-printed design process and perform a cost comparison with the standard of care process
Timepoint [7] 0 0
5 years
Secondary outcome [8] 0 0
To assess patient experience and acceptability of the process with questionnaires
Timepoint [8] 0 0
5 years

Eligibility
Key inclusion criteria
* Able to give informed consent
* Patients indicated for intracavitary brachytherapy
* FIGO stage I-IVA
* ECOG 0-2
* Primary endometrial cancer, primary vaginal cancer, primary vulva cancer, recurrent gynaecological cancer
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnancy
* Patients contraindicated for brachytherapy
* Inflammatory bowel disease/history of adhesions/bowel obstruction
* Renal transplant/horseshoe kidney
* Patients with significant LVSI or pelvic sidewall invasion
* Patients requiring interstitial brachytherapy implants

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/11/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2028
Actual
Sample size
Target
10
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 0 0
2067 - St Leonards

Funding & Sponsors
Primary sponsor type
Other
Name
Royal North Shore Hospital
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Marita Morgia, MD
Address 0 0
Royal North Shore Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Marita Morgia, MD
Address 0 0
Country 0 0
Phone 0 0
9463 1300
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06432478